Finanzen von eXoZymes Inc (EXOZ)EXOZeXoZymes Inc

Evaluating the bottom line, eXoZymes Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -187.16%, provide a clear picture of how effectively EXOZ converts its operational activities into shareholder value.

In the context of the broader market, EXOZ competes directly with industry leaders such as UG and LOOP. With a market capitalization of $54.02M, it holds a leading position in the sector. When comparing efficiency, EXOZ's gross margin of N/A stands against UG's 49.73% and LOOP's -46.93%. Such benchmarking helps identify whether eXoZymes Inc is trading at a premium or discount relative to its financial performance.

Exozymes has reported continuous losses, with net income reaching -2,878,614 USD in Q2 2026 and an EPS of -0.33. The company's financial health is further reflected in a current ratio of 3.81, indicating some liquidity, but the overall trend remains negative with a debt to equity ratio of 6.41% in Q1 2026.